Top

Wits RHI

IMPAACT 2040

Vaccine Preventable Diseases

IMPAACT 2040, or CREATE, is a phase I/II study of the pharmacokinetics and safety of long-acting injectable cabotegravir and rilpivirine in pregnant and postpartum women with HIV-1. Long-acting ART, such as CAB LA + RPV LA, has the potential to improve treatment outcomes for individuals living with HIV-1, including during pregnancy. It will provide monthly or two-monthly injections as an alternate to daily oral ART and precludes the clinically significant barriers of pill burden, daily adherence, and disclosure of HIV-1 status. Wits RHI Shandukani CRS has excellent experience in long-acting injectable ART clinical trials, having been part of studies such as MOCHA and CRAYON, which focused on adolescent and paediatric populations. Enrolment is planned to start in late Q1 of 2025.

Investigators

  • Dr Mrinmayee Dhar, Principal Investigator

Latest Update

March 2025

For more information about IMPAACT 2040, please email rhicomms@wrhi.ac.za.